Glenmark Pharmaceuticals Limited
GLENMARK
Classifica tra le azioni
#2735
Glenmark Pharmaceuticals Limited, including its associated entities, is a... Glenmark Pharmaceuticals Limited, including its associated entities, is a global pharmaceutical company specializing in the research, development, production, and marketing of medicinal products. Its operational reach spans India, North America, Latin America, Europe, and other international regions. The company's diverse offerings comprise both branded and generic drug formulations, with a strategic emphasis on therapeutic areas such as dermatology, respiratory conditions, and oncology. Additionally, Glenmark manufactures and supplies a variety of active pharmaceutical ingredients. The company's robust product pipeline includes several investigational therapies. Among its clinical-stage assets are ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody currently in Phase 2b trials for atopic dermatitis; ISB 1302, a HER2 x CD3 bispecific antibody undergoing Phase 1/2 studies for metastatic HER2-positive breast cancer; and ISB 1342, a CD38 x CD3 bispecific antibody in Phase 1 development for relapsed/refractory multiple myeloma. In its preclinical pipeline, Glenmark is advancing ISB 880 for anti-inflammatory applications; the T-cell engagers ISB 1908 and ISB 1909 for oncology indications; ISB 1442, an innate immune engager also targeting oncology; and GRC 39815, a retinoid-related orphan receptor gamma inhibitor aimed at treating chronic obstructive pulmonary disorder (COPD). Among its commercially available products is Ryaltris nasal spray, prescribed for allergic rhinitis. Founded in 1977, Glenmark Pharmaceuticals Limited is headquartered in Mumbai, India.
Prezzo delle azioni
$24.39
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$6.88B
Variazione (1 giorno)
-1.20%
Variazione (1 anno)
15.69%
Paese
IN
Scambia Glenmark Pharmaceuticals Limited (GLENMARK)
Categoria
Healthcare
Rapporto P/B per Glenmark Pharmaceuticals Limited (GLENMARK)
Rapporto P/B al October 2026 TTM: 6.08
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Glenmark Pharmaceuticals Limited, il rapporto P/B attuale (TTM) è 6.08. Alla fine del 2024, era pari a 3.53.
Storico del rapporto P/B per Glenmark Pharmaceuticals Limited da 2004 a 2026
Rapporto P/B alla fine di ogni anno
| Anno | Rapporto P/B | Cambia |
|---|---|---|
| 2026 (TTM) | 6.08 | 26.36% |
| 2025 | 4.81 | 36.24% |
| 2024 | 3.53 | 155.23% |
| 2023 | 1.38 | 0.84% |
| 2022 | 1.37 | -26.05% |
| 2021 | 1.86 | 93.99% |
| 2020 | 0.96 | -70.90% |
| 2019 | 3.29 | 18.97% |
| 2018 | 2.76 | -43.22% |
| 2017 | 4.87 | -6.87% |
| 2016 | 5.23 | -26.46% |
| 2015 | 7.11 | 38.42% |
| 2014 | 5.13 | 12.35% |
| 2013 | 4.57 | 31.20% |
| 2012 | 3.48 | -7.37% |
| 2011 | 3.76 | 26.48% |
| 2010 | 2.97 | 21.13% |
| 2009 | 2.45 | -68.85% |
| 2008 | 7.88 | -25.67% |
| 2007 | 10.60 | 11.49% |
| 2006 | 9.51 | -6.82% |
| 2005 | 10.21 | 191.16% |
| 2004 | 3.51 | 0.00% |
Rapporto P/B per aziende simili o concorrenti
| Azienda | Rapporto P/B | Differenza del rapporto P/B | Il paese |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | -17.06% |
IN
|
